Advanced search
Publication Cover
Leukemia & Lymphoma Volume 47, 2006 - Issue 12
Submit an article Journal homepage
89
Views
2
CrossRef citations to date
0
Altmetric
Original

Prognostic factors for the efficacy of thalidomide in the treatment of multiple myeloma: A clinical study of 110 patients in China

Yonghua Li Department of Hematology, Changzheng Hospital, The Second Military Medical University, Shanghai, PR, China
,
Jian Hou Department of Hematology, Changzheng Hospital, The Second Military Medical University, Shanghai, PR, ChinaCorrespondence[email protected]
,
Dongxing Wang Department of Hematology, Changzheng Hospital, The Second Military Medical University, Shanghai, PR, China
,
Weijun Fu Department of Hematology, Changzheng Hospital, The Second Military Medical University, Shanghai, PR, China
,
Zhengang Yuan Department of Hematology, Changzheng Hospital, The Second Military Medical University, Shanghai, PR, China
,
Yubao Chen Department of Hematology, Changzheng Hospital, The Second Military Medical University, Shanghai, PR, China
&
Zhongfei Tao Department of Hematology, Changzheng Hospital, The Second Military Medical University, Shanghai, PR, China
 show all
Pages 2593-2600 | Received 28 Mar 2006, Accepted 10 Aug 2006, Published online: 01 Jul 2009

References

  • Myeloma Trialists' Collaborative Groupe. Combination chemotherapy versus melphalan and prednisone as treatment for multiple myeloma: an review of 6,633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832–3842
  • Bensinger W I, Buckner C D, Anasetti C, Clift R, Storb R, Barnett T, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787–2793
  • Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
  • Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123
  • Moreira A L, Sampaio E P, Zmuidzinas A, Frindt P, Smith K A, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675–1680
  • Sampaio E P, Sarno E N, Galilly R, Cohn Z A, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699–703
  • Singhal S, Mehta J. Thalidomide in cancer: potential uses and limitations. BioDrugs 2001; 15: 63–72
  • Rowland T L, McHugh S M, Deighton J, Dearman R J, Ewan P W, Kimber I. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology 1998; 40: 11–20
  • Damiano J S, Cress A E, Hazlehurst L A, Shtil A A, Dalton W S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658–1667
  • Haslett P A, Corral L G, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187: 1885–1892
  • Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492–494
  • Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121: 768–777
  • Moehler T M, Neben K, Benner A, Egerer G, Krasniqi F, Ho A D, et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001; 98: 3846–3848
  • Mileshkin L, Biagi J J, Mitchell P, Underhill C, Grigg A, Bell R, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003; 102: 69–77
  • Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho A D, et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002; 8: 3377–3382
  • Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35–39
  • Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030
  • Brinker B T, Waller E K, Leong T, Heffner L T, Redei I, Langston A A, et al. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer 2006; 106: 2171–2180
  • Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma 2003; 4: 32–35
  • Durie B G, Stock-Novack D, Salmon S E, Finley P, Beckord J, Crowley J, et al. Prognostic value of pretreatment serum beta2 microglobulin in myeloma: A Southwest Oncology Group study. Blood 1990; 75: 823–830
  • Jacobson J L, Hussein M A, Barlogie B, Durie B G, Crowley J J. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 2003; 122: 441–450
  • Greipp P R, San Miguel J, Durie B G, Crowley J J, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.